How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegeneration through toll-like receptor TLR signaling and short-chain fatty acids SCFAs
The gap can be tested by treating TLR4 priming as an upstream driver rather than a passive correlate. If true, perturbing butyrate-restoring consortia should shift fecal butyrate before downstream neurodegeneration markers change.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Gut Dysbiosis SCFA-Producing Bacteria Loss"]
B["Intestinal Permeability Leaky Gut Endotoxemia"]
C["LPS Translocation Portal and Systemic Circulation"]
D["TLR4 Activation MD-2 Coreceptor Complex"]
E["MyD88 Signaling NF-kappaB and MAPK Cascade"]
F["Peripheral Cytokine Storm IL-1beta and TNF Secretion"]
G["Microglial Priming Brain Resident Immune Activation"]
H["Neurodegeneration Synapse Loss and Tau Pathology"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
G --> H
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Median TPM across 13 brain regions for TLR4 priming from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations5 with PMID5 mediumValidation: 75%6 supporting / 1 opposing
✓For(6)
5
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
2
1
MECH 4CLIN 0GENE 2EPID 1
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
TLR4 and CD14 trafficking and its influence on LPS…
causal direction requires longitudinal perturbation
skeptic_round
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
💬 Discussion
Loading comments...
No DepMap CRISPR Chronos data found for TLR4 priming.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
IF TLR4 priming is the gut-dysbiosis driver of neuroinflammation, THEN fecal microbiota transfer from dysbiotic donors will raise microglial TLR4/NF-kB activation by >=30% within 6 weeks in germ-free mice.
pendingconf: 0.65
Expected outcome: Recipient mice show >=30% increase in microglial TLR4/NF-kB activation markers versus healthy-donor FMT recipients.
Falsified by: Activation increase is <10% or is unchanged by TLR4 blockade.
Method: Germ-free or antibiotic-treated mouse FMT study with brain microglia flow/single-cell profiling at 6 weeks.
IF TLR4 is actionable upstream, THEN pharmacologic or genetic TLR4 inhibition will prevent at least 50% of dysbiosis-induced IL-1B/TNF microglial upregulation within 8 weeks.
pendingconf: 0.62
Expected outcome: TLR4 inhibition reduces dysbiosis-induced microglial IL-1B/TNF signal by >=50% versus untreated dysbiotic controls.
Falsified by: TLR4 inhibition reduces cytokine signal by <20% despite target engagement.
Method: Dysbiosis mouse model with TLR4 inhibitor or knockout arm, cytokine and microglial-state endpoints at 8 weeks.